No Data
KINGWORLD: Interim Report 2024
Kingworld Pharmaceutical Group (01110): Chu Xiaoping appointed as an independent non-executive director
Kingworld (01110) announced that Dr. Chu Xiaoping has been appointed as an independent non-executive director, nomination committee,...
Kingworld Appoints New Independent Director
Kingworld Medicines Unveils New Board Structure
Jinhuo Medicine (01110.HK) is innovating and creating a new engine.
With the approaching of the expected interest rate cut by the Federal Reserve and the increase of policy support, the pharmaceutical sector has become a focus area in the market due to its low valuation and high cost-effectiveness. Several brokerages predict that after the release of the mid-year report, the negative factors in the pharmaceutical industry will be effectively digested, indicating that the second half of the year will be a golden opportunity to layout in this sector. Particularly noteworthy is the recent announcement of the performance of Kingworld Pharmaceutical Group Co., Ltd. (referred to as 'Kingworld Pharmaceutical') for the first half of 2024, which has demonstrated strong resilience and stabilized the company's fundamentals in the industry's generally cool environment. The company has long been deeply involved in the pharmaceutical market and owns various brands including 'Made in China'.
KINGWORLD: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
No Data
No Data